Gongwin Biopharm Holdings Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	36.45	32.04	18.92	1.14	1.14
Revenue Growth (YoY)	13.75%	69.39%	1554.86%	-	37.21%
Cost of Revenue	10.36	23.36	7.72	0.08	0.07
Gross Profit	26.09	8.68	11.2	1.07	1.08
Selling, General & Admin	115.55	101.56	91.88	67.43	38.85
Research & Development	119.47	63.27	52.65	194.32	83.05
Operating Expenses	233.38	170.74	144.53	261.75	121.9
Operating Income	-207.29	-162.06	-133.33	-260.68	-120.83
Interest Expense	-5.16	-4.3	-7.19	-3.19	-1.18
Interest & Investment Income	70.81	64.62	41.61	6.82	2.4
Currency Exchange Gain (Loss)	-	-4.69	-4.85	-39.6	0.9
Other Non Operating Income (Expenses)	20.77	3.47	2.58	4.51	2.05
EBT Excluding Unusual Items	-120.87	-102.96	-101.18	-292.13	-116.66
Gain (Loss) on Sale of Investments	-	11.11	-	-	0.74
Gain (Loss) on Sale of Assets	-	-0	-	-	-
Other Unusual Items	-	-	-	-	1.2
Pretax Income	-120.87	-91.86	-101.18	-292.13	-114.72
Income Tax Expense	0.16	0.13	-	-	15.2
Earnings From Continuing Operations	-121.03	-91.99	-101.18	-292.13	-129.92
Minority Interest in Earnings	6.9	9.44	9.14	-	8.34
Net Income	-114.13	-82.55	-92.04	-292.13	-121.58
Net Income to Common	-114.13	-82.55	-92.04	-292.13	-121.58
Shares Outstanding (Basic)	124	121	113	111	110
Shares Outstanding (Diluted)	124	121	113	111	110
Shares Change (YoY)	2.70%	6.64%	1.92%	1.44%	4.87%
EPS (Basic)	-0.92	-0.68	-0.81	-2.63	-1.11
EPS (Diluted)	-0.92	-0.68	-0.81	-2.63	-1.11
Free Cash Flow	-137.62	-293.3	-111.7	-239.54	-218.52
Free Cash Flow Per Share	-1.11	-2.43	-0.99	-2.15	-2.00
Gross Margin	71.58%	27.09%	59.21%	93.26%	94.31%
Operating Margin	-568.76%	-505.80%	-704.87%	-22806.74%	-10570.95%
Profit Margin	-313.14%	-257.64%	-486.58%	-25558.44%	-10637.01%
Free Cash Flow Margin	-377.59%	-915.41%	-590.55%	-20956.69%	-19118.11%
EBITDA	-195.57	-153.87	-125.03	-252.2	-112.82
D&A For EBITDA	11.72	8.19	8.29	8.48	8
EBIT	-207.29	-162.06	-133.33	-260.68	-120.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.